A Blend Certificate Cannot Report a Single Purity Figure

Putting several compounds into one vial and lyophilizing them together is a packaging choice, not a chemical one. What it does change is how much the label and the certificate can actually tell you. Nearly all the confusion surrounding blends traces back to a single habit: reading a blend number as though it referred to one compound.

Everything on the label is added together

An 80mg designation describes the combined mass of all components, never the amount of any individual one. KLOW 80mg breaks down as BPC-157 10mg, TB-500 10mg, GHK-Cu 50mg and KPV 10mg. GLOW 70mg carries the first three of those and leaves the KPV out.

Which means the dominant component is usually not the one people expect. GHK-Cu accounts for about two-thirds of the mass in both of those blends. Set a blend price against a single-compound price per milligram without correcting for that and the resulting number means nothing; the general form of the mistake is unpacked in this look at comparing peptide prices per milligram.

A single purity percentage cannot describe a mixture

HPLC purity is calculated as main peak area over the total area of everything the detector saw. Deliberately, a blend has no one main peak. It has several.

A bare percentage on a blend certificate is therefore ambiguous at best. Ninety-eight percent of what, exactly? Should the integration lump all four component peaks together as a combined main peak, the number describes the vial in aggregate while saying nothing about whether the components sit in their intended proportions. Should it instead call one peak the main and the others impurities, the number is simply wrong.

Two defensible ways to certify a blend

Either approach beats a lone percentage. The first tests components before blending: every compound is analyzed by itself, gets its own identity and purity result, and the blend is then built from material that was already characterized. The second runs the finished blend and resolves each component as a discrete peak, identified by retention against a standard, with the areas reported one by one.

Whichever route is taken, the chromatogram is the thing to request rather than the summary. Four compounds should yield four resolved peaks, and anything that co-elutes cannot be quantified separately regardless of what a certificate asserts. How to interpret one is covered in reading an HPLC chromatogram and in what a third-party peptide test actually measures.

Identity is the easier half

Mass spectrometry handles mixtures far better than purity analysis does. Each component contributes its own parent mass, and those masses are separated widely enough to leave no ambiguity: BPC-157 near 1419.5, TB-500 at 889.0, and GHK-Cu, as the copper complex, near 402.9. Observing every expected mass confirms that every component is in the vial. It says nothing about their relative amounts, which requires quantitative work against known standards.

Copper changes the chemistry of the container

GHK-Cu is a coordination complex rather than a peptide in the usual sense, a tripeptide with a copper ion bound to it. Blended, it carries that copper along, and copper is redox-active. That matters whenever a blend also includes a component containing methionine or tryptophan, since transition metals catalyze oxidation at precisely those residues.

Neither BPC-157 nor TB-500 has methionine or tryptophan in its sequence, so the familiar tissue blends behave well on this front. The point is to reason about composition rather than to assume any blend behaves exactly like its components kept in separate vials. What the copper does and does not alter is set out in the article on GHK and GHK-Cu.

Stability defaults to the weakest component

Whatever is most fragile in the vial governs the vial. Components sharing a container cannot be stored under separate conditions, and they cannot be reconstituted at separate times. When one compound is the one that reacts to light, to oxygen or to repeated entry, that sensitivity is inherited by everything alongside it. The relevant variables are laid out in the storage and stability article.

Separation is off the table

Obvious, but it bears saying: once compounds have been lyophilized together, no practical bench procedure recovers them individually. All components meet the same solvent at the same moment, at concentrations locked to the ratio in the vial. Where an experimental design calls for independent concentrations, or for one compound by itself, the single-compound listings are the place to begin. BPC-157, TB-500, GHK-Cu, CJC-1295 without DAC and Ipamorelin are each stocked individually.

One dilution, four concentrations

With the composition in hand the arithmetic takes a moment. Reconstitute an 80mg KLOW vial into 4mL and the solution is nominally 2.5mg/mL BPC-157, 2.5mg/mL TB-500, 12.5mg/mL GHK-Cu and 2.5mg/mL KPV. A single dilution step produces four distinct concentrations. Net peptide content applies separately to each component, which places all four nominal figures above the true peptide mass; the size of that gap is explained in the net peptide content article.

Blends held in stock

Currently listed are KLOW 80mg, GLOW 70mg, BPC-157 & TB-500 10mg, BPC-157 & TB-500 20mg and CJC-1295 & Ipamorelin 10mg. Composition is stated on each product page, and the third-party reports we have published can be found on the certificates of analysis page. Every item is supplied strictly for laboratory research use. We publish no dosing information, no protocols involving human or veterinary subjects, and no statements about what any component does in a person.